10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
65.05
+5.77 (9.73%)
At close: Nov 9, 2026, 4:00 PM EST
65.84
+0.79 (1.21%)
After-hours: Nov 9, 2026, 7:55 PM EST
10x Genomics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, 10x Genomics stock has a consensus rating of "Buy" and an average price target of $68.14. The average 1-year stock price forecast is 4.75% higher than the current stock price, while the lowest is $50 (-23.14%) and the highest is $100 (+53.73%).
Price Target: $68.14 (+4.75%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 9 | 9 | 9 | 11 | 11 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Reiterates $70 → $65 | Hold | Reiterates | $70 → $65 | -0.08% | Nov 9, 2026 |
| UBS | UBS | Hold Reiterates $90 → $61 | Hold | Reiterates | $90 → $61 | -6.23% | Nov 9, 2026 |
| Barclays | Barclays | Buy Maintains $110 → $70 | Buy | Maintains | $110 → $70 | +7.61% | Nov 9, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Nov 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $100 | Buy | Reiterates | $100 | +53.73% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
631.05M
from 642.82M
Decreased by -1.83%
Revenue Next Year
703.42M
from 631.05M
Increased by 11.47%
EPS This Year
0.06
from 0.12
Decreased by -48.55%
EPS Next Year
0.09
from 0.06
Increased by 36.85%
EPS and Forward PE are based on non-GAAP adjusted numbers.